Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, ...

Bristol-Myers Squibb’s stock faces skepticism, but its promising drugs like Cobenfy could change the game. Cobenfy, a ...

With an average analyst rating of hold, Bristol-Myers Squibb is clearly not a favorite. But some of the best stock picks are ...

Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...